MJMichael V. Johnston

Michael V. Johnston

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael V. Johnston has a total of 271 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recent advances in perinatal neuroprotection

    by Samata Singhi, Michael Johnston

    Perinatal brain injury is a major cause of neurological disability in both premature and term infants. In this review, we summarize the evidence behind some established neuroprotective practices such as administration of antenatal steroids, intrapartum magnesium for preterm delivery, and therapeutic hypothermia. In addition, we examine emerging practices such as delayed cord clamping, postnatal magnesium administration, recombinant erythropoietin, and non-steroidal anti-inflammatory agents and finally inform the reader about novel interventions, some of which are currently in trials, such as xenon, melatonin, topiramate, allopurinol, creatine, and autologous cord cell therapy.


  • Correlating Oxygen Delivery During Cardiopulmonary Bypass With the Neurologic Injury Biomarker Ubiquitin C-Terminal Hydrolase L1 (UCH-L1)

    by J. Trent Magruder, Charles D. Fraser, Joshua C. Grimm, Todd C. Crawford, Claude A. Beaty, Alejandro Suarez-Pierre, Ronald L. Hayes, Michael V. Johnston, William A. Baumgartner


  • Open Access

    Dendrimer-mediated delivery of N-acetyl cysteine to microglia in a mouse model of Rett syndrome

    by Elizabeth Nance, Siva P. Kambhampati, Elizabeth S. Smith, Zhi Zhang, Fan Zhang, Sarabdeep Singh, Michael V. Johnston, Rangaramanujam M. Kannan, Mary E. Blue, Sujatha Kannan

    Rett syndrome (RTT) is a pervasive developmental disorder that is progressive and has no effective cure. Immune dysregulation, oxidative stress, and excess glutamate in the brain mediated by glial dysfunction have been implicated in the pathogenesis and worsening of symptoms of RTT. In this study, we investigated a new nanotherapeutic approach to target glia for attenuation of brain inflammation/injury both in vitro and in vivo using a Mecp2-null mouse model of Rett syndrome. To determine whether inflammation and immune dysregulation were potential targets for dendrimer-based therapeutics in RTT, we assessed the immune response of primary glial cells from Mecp2-null and wild-type (WT) mice to LPS. Using dendrimers that intrinsically target activated microglia and astrocytes, we studied N-acetyl cysteine (NAC) and dendrimer-conjugated N-acetyl cysteine (D-NAC) effects on inflammatory cytokines by PCR and multiplex assay in WT vs Mecp2-null glia. Since the cysteine-glutamate antiporter (Xc−) is upregulated in Mecp2-null glia when compared to WT, the role of Xc− in the uptake of NAC and l-cysteine into the cell was compared to that of D-NAC using BV2 cells in vitro. We then assessed the ability of D-NAC given systemically twice weekly to Mecp2-null mice to improve behavioral phenotype and lifespan. We demonstrated that the mixed glia derived from Mecp2-null mice have an exaggerated inflammatory and oxidative stress response to LPS stimulation when compared to WT glia. Expression of Xc− was significantly upregulated in the Mecp2-null glia when compared to WT and was further increased in the presence of LPS stimulation. Unlike NAC, D-NAC bypasses the Xc− for cell uptake, increasing intracellular GSH levels while preventing extracellular glutamate release and excitotoxicity. Systemically administered dendrimers were localized in microglia in Mecp2-null mice, but not in age-matched WT littermates. Treatment with D-NAC significantly improved behavioral outcomes in Mecp2-null mice, but not survival. These results suggest that delivery of drugs using dendrimer nanodevices offers a potential strategy for targeting glia and modulating oxidative stress and immune responses in RTT.


  • Open Access

    The Quest for Neuroprotection for Injuries in the Developing Brain

    by Fatima Yousif Ismail, Ali Fatemi, Michael Johnston

    The advancement in medical knowledge could have not been possible without interlocking and reinforcing the bedside-lab continuum. In the field of pediatric neurology, one of the best illustrative examples is our quest for finding neuroprotective therapies in the setting of neonatal hypoxic-ischemic encephalopathy. In this review, we discuss the careful clinical observations driven from the bedside dating back to the work of Frank Ford. We trace the relentless efforts to emulate the pathogenesis in animal models to testing potential therapies in clinical trials that made the transfer of this knowledge back to the bedside possible in order to save and improve the quality of life for hundred of thousands of newborns who suffered hypoxic ischemic insult.


  • Open Access

    New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND)

    by Tanjala T. Gipson, Michael V. Johnston

    Tuberous sclerosis complex (TSC) is a multi-system disorder resulting from mutations in either theTSC1orTSC2genes leading to hyperactivation of mechanistic target of rapamycin (mTOR) signaling. TSC is commonly associated with autism (61%), intellectual disability (45%), and behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties that are collectively referred to as TSC-associated neuropsychiatric disorders (TAND). More than 90% of children with TSC have epilepsy, including infantile spasms, and early onset of seizures, especially infantile spasms, is associated with greater impairment in intellectual development compared with individuals with TSC without seizures. Development of the mTOR inhibitors everolimus and sirolimus has led to considerable progress in the treatment of renal angiomyolipomata, pulmonary lymphangioleiomyomatosis, and subependymal giant cell astrocytomas in the brain. However, similar therapeutic progress is needed in the treatment of TAND.


  • Neonatal Brain Injuries

    by Katharina Goeral, Ali Fatemi, Michael V. Johnston

    Neonatal brain injuries (NBIs) are important causes of motor and neurocognitive disabilities in children worldwide. This chapter discusses the most common types of NBIs in developed countries, namely neonatal encephalopathy associated with birth asphyxia in term infants, perinatal arterial ischemic stroke, perinatal white matter injury, and germinal matrix hemorrhage and neonatal hydrocephalus. Epidemiologic studies suggest that prenatal stressors, including intrauterine inflammation, maternal drug/toxin exposure, and placental pathologies are key players in the etiology of NBIs, whereas genetic contributors are yet to be identified. Hypothermia has become a standard neuroprotective strategy in neonatal encephalopathy, and novel therapeutics are currently being evaluated.

  • Tuberous Sclerosis Complex

    by Tanjala T. Gipson, Andrea Poretti, Rebecca McClellan, Michael V. Johnston

    Tuberous sclerosis complex (TSC) is a disease, commonly classified as a neurocutaneous disorder, which may result in benign tumors throughout the brain and body, skin lesions, epilepsy, and cognitive/behavioral difficulties. Scientific discovery in TSC has resulted in the availability of treatments designed to target the neurobiological core of TSC in children. However, research is needed to determine if these treatments are effective for multiple aspects of the TSC phenotype in children. Current pediatric research studies have focused on the effects of early treatment of epilepsy as well as identification of potential biomarkers. This chapter reviews the aspects of TSC unique to pediatric patients, the status of current research, and future directions.

  • Brain Abscess

    by Bela R. Turk, Ali Fatemi, Michael V. Johnston

    Brain abscess provides a challenging clinical problem and a medical emergency. Multiple mechanisms of pathogen dissemination and a wide spectrum of etiologic agents source the varying intracranial locations of infection. Due to this, the disease presents in a divergent and nonspecific manner. Timely diagnosis and imaging studies are crucial to improve outcomes as well as individual neurological and neurosurgical case management.

  • Overview of Autism and Intellectual Disabilities

    by Tanjala T. Gipson, Michael V. Johnston

    Autism spectrum disorders (ASD) and intellectual disabilities (ID) are prevalent causes of brain dysfunction in childhood and they have a significant public health impact on quality of life and the ability to live independently. ID is defined by the presence of an intelligence quotient less than 70 on a standardized test combined with impaired adaptive skills of daily living, whereas autism is defined by a combination of impaired language and social skills as well as the presence of stereotyped movements or behaviors. The prevalence of ID is estimated to be 1/100 population, with higher numbers in low resource countries, whereas the prevalence of autism is estimated to be 1 in 68, 1/42 boys and 1/189 girls. Approximately 70% of individuals with autism also meet the criteria for ID, but ID is not necessary for the diagnosis of autism. Genetic disorders are an important cause of autism, and 80% of identical twins will share autism if it is present in one twin, whereas the rate of concurrence in fraternal twins is 30%. This overview describes some general features of the causation and neurobiology of ID and ASD that are discussed in more detail in the chapters on specific pediatric disorders later in this section.

  • Open Access

    Cerebral Reorganization after Hemispherectomy: A DTI Study

    by A. Meoded, A. V. Faria, A. L. Hartman, G. I. Jallo, S. Mori, M. V. Johnston, T. A. G. M. Huisman, A. Poretti

    BACKGROUND AND PURPOSE: Hemispherectomy is a neurosurgical procedure to treat children with intractable seizures. Postsurgical improvement of cognitive and behavioral functions is observed in children after hemispherectomy suggesting plastic reorganization of the brain. Our aim was to characterize changes in DTI scalars in WM tracts of the remaining hemisphere in children after hemispherectomy, assess the associations between WM DTI scalars and age at the operation and time since the operation, and evaluate the changes in GM fractional anisotropy values in patients compared with controls. MATERIALS AND METHODS: Patients with congenital or acquired neurologic diseases who required hemispherectomy and had high-quality postsurgical DTI data available were included in this study. Atlas- and voxel-based analyses of DTI raw data of the remaining hemisphere were performed. Fractional anisotropy and mean, axial, and radial diffusivity values were calculated for WM and GM regions. A linear regression model was used for correlation between DTI scalars and age at and time since the operation. RESULTS: Nineteen patients after hemispherectomy and 21 controls were included. In patients, a decrease in fractional anisotropy and axial diffusivity values and an increase in mean diffusivity and radial diffusivity values of WM regions were observed compared with controls (P < .05, corrected for multiple comparisons). In patients with acquired pathologies, time since the operation had a significant positive correlation with white matter fractional anisotropy values. In all patients, an increase in cortical GM fractional anisotropy values was found compared with controls (P < .05). CONCLUSIONS: Changes in DTI metrics likely reflect Wallerian and/or transneuronal degeneration of the WM tracts within the remaining hemisphere. In patients with acquired pathologies, postsurgical fractional anisotropy values correlated positively with elapsed time since the operation, suggesting a higher ability to recover compared with patients with congenital pathologies leading to hemispherectomy.